[go: up one dir, main page]

SI3686194T1 - 2-(2,4,5-substituted-anilino)pyrimidine compounds - Google Patents

2-(2,4,5-substituted-anilino)pyrimidine compounds

Info

Publication number
SI3686194T1
SI3686194T1 SI201231963T SI201231963T SI3686194T1 SI 3686194 T1 SI3686194 T1 SI 3686194T1 SI 201231963 T SI201231963 T SI 201231963T SI 201231963 T SI201231963 T SI 201231963T SI 3686194 T1 SI3686194 T1 SI 3686194T1
Authority
SI
Slovenia
Prior art keywords
anilino
substituted
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
SI201231963T
Other languages
Slovenian (sl)
Inventor
Sam Butterworth
Richard Andrew Ward
Maurice Raymond Verschoyle Finlay
Vasantha Krishna Kadambar
Chandrasekhara Reddy Chintakuntla
Andiappan Murugan
Claudio Edmundo Chuaqui
Heather Marie Redfearn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3686194(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI3686194T1 publication Critical patent/SI3686194T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Luminescent Compositions (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SI201231963T 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine compounds SI3686194T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27
US201261591363P 2012-01-27 2012-01-27
EP20157927.3A EP3686194B1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine compounds

Publications (1)

Publication Number Publication Date
SI3686194T1 true SI3686194T1 (en) 2022-01-31

Family

ID=46875901

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201231771T SI3333161T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
SI201231963T SI3686194T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine compounds
SI201231167T SI3009431T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
SI201230455T SI2736895T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201231771T SI3333161T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI201231167T SI3009431T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
SI201230455T SI2736895T1 (en) 2011-07-27 2012-07-25 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Country Status (38)

Country Link
US (8) US8946235B2 (en)
EP (7) EP3686193B1 (en)
JP (3) JP5427321B2 (en)
KR (3) KR101422619B1 (en)
CN (7) CN105198862B (en)
AR (1) AR087336A1 (en)
AU (1) AU2012288626C1 (en)
BR (4) BR122014026094B1 (en)
CA (5) CA2881993C (en)
CL (1) CL2013003281A1 (en)
CO (1) CO6811863A2 (en)
CR (1) CR20130629A (en)
CY (4) CY1117431T1 (en)
DK (5) DK3686193T3 (en)
DO (1) DOP2013000263A (en)
EA (3) EA033733B1 (en)
EC (1) ECSP13013033A (en)
ES (5) ES2564671T3 (en)
GT (1) GT201300288A (en)
HR (4) HRP20211682T1 (en)
HU (4) HUE026429T2 (en)
IL (6) IL229199A (en)
LT (3) LT3009431T (en)
ME (3) ME02887B (en)
MX (3) MX377900B (en)
MY (2) MY161925A (en)
NI (1) NI201300134A (en)
PE (1) PE20141700A1 (en)
PH (2) PH12013502312A1 (en)
PL (5) PL3333161T3 (en)
PT (4) PT3009431T (en)
RS (4) RS56679B1 (en)
SG (5) SG10201402860QA (en)
SI (4) SI3333161T1 (en)
SM (3) SMT202100652T1 (en)
TW (3) TWI465445B (en)
UY (1) UY34219A (en)
WO (1) WO2013014448A1 (en)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2300013T (en) 2008-05-21 2017-10-31 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
PL2467387T3 (en) 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
PT3009431T (en) 2011-07-27 2017-12-26 Astrazeneca Ab 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN105408336B (en) * 2013-01-29 2018-06-26 阿普廷伊克斯股份有限公司 Spiro-lactam NMDA receptor modulators and uses thereof
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014210354A1 (en) * 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
CN104292142B (en) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 A kind of de- aryl method of N- aryl-heterocyclic butane
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
TR201911140T4 (en) * 2013-10-21 2019-08-21 Merck Patent Gmbh Heteroaryl compounds and their uses as Btk inhibitors.
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104761544B (en) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 The selective depressant of the important mutant of clinic of EGFR tyrosine kinase
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
CN104860941B (en) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative
EP3125885B1 (en) * 2014-04-04 2021-06-30 Astrazeneca AB Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP6468611B2 (en) * 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド Heteroaryl compounds for kinase inhibition
CN111892579B (en) * 2014-06-12 2023-07-25 上海艾力斯医药科技股份有限公司 Kinase inhibitors
EP3157916B1 (en) * 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105254615B (en) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers
CN105315285B (en) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4 2 substitution 7H pyrrolo-es [2,3 d] pyrimidine derivatives, its preparation method and purposes pharmaceutically
CN105315259B (en) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 Pyridine amine pyrimidine derivates, its preparation method and application
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
CN104140418B (en) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2,4,5-substituted aniline) pyrimidine derivatives and application thereof
CN113121575A (en) * 2014-08-25 2021-07-16 四川海思科制药有限公司 (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof
CN104356040A (en) * 2014-09-17 2015-02-18 爱斯特（成都）生物制药有限公司 Preparation method of 1-benzhydryl-3-hydroxylazetidine hydrochloride
CN105461695B (en) * 2014-09-29 2018-03-27 齐鲁制药有限公司 Pyrimidine or pyrrolotriazine derivatives and its production and use
CN105524068B (en) * 2014-09-30 2017-11-24 上海海雁医药科技有限公司 Azabicyclic derivatives, its preparation method and purposes pharmaceutically
CN105237515B (en) * 2014-10-10 2018-06-05 益方生物科技（上海）有限公司 Deuterated pyrimidines, its preparation method, pharmaceutical composition and purposes
US10259820B2 (en) * 2014-10-11 2019-04-16 Shanghai Hansoh Biomedical Co., Ltd. EGFR inhibitor, preparation method and use thereof
TWI730331B (en) * 2014-10-13 2021-06-11 南韓商柳韓洋行股份有限公司 Compounds and compositions for modulating egfr mutant kinase activities
CN105085489B (en) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 Pyrimidine or pyridine compound, its preparation method and medical use
CN114224894B (en) * 2014-12-03 2025-01-07 奥克兰联合服务有限公司 Kinase inhibitor prodrugs for the treatment of cancer
WO2016094821A2 (en) * 2014-12-11 2016-06-16 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
CN113563332B (en) * 2014-12-23 2024-12-17 达纳－法伯癌症研究所公司 Novel pyrimidines as EGFR inhibitors and methods of treating disorders
CN104788427B (en) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application
CN104961731A (en) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2016173438A1 (en) 2015-04-29 2016-11-03 南京明德新药研发股份有限公司 Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
TWI685494B (en) * 2015-04-29 2020-02-21 大陸商廣東眾生藥業股份有限公司 Fused-ring or tricyclic aryl pyridine compuond used as kinase inhibitor
CN104817541B (en) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 A kind of synthetic method of antineoplastic
US20210323976A1 (en) * 2015-05-13 2021-10-21 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
HK1250638A1 (en) 2015-05-15 2019-01-11 Novartis Ag Methods for treating egfr mutant cancers
CN104910049B (en) * 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 AZD9291 intermediate and preparation method thereof
US10329277B2 (en) 2015-07-16 2019-06-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity
US10550112B2 (en) 2015-07-20 2020-02-04 Dana-Farber Cancer Institute, Inc. Pyrimidines as EGFR inhibitors and methods of treating disorders
CN107531678B (en) * 2015-07-24 2020-12-22 上海海雁医药科技有限公司 EGFR inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof
CN105001208A (en) * 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 EGFR inhibitor and preparing method and application thereof
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
JP6606278B2 (en) * 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド 2-Arylaminopyridine, pyrimidine or triazine derivatives and their production and use
CN106117185B (en) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4 2 nitrogen-containing group substituted uracil compounds and its preparation method and application
CN106478605A (en) * 2015-09-02 2017-03-08 上海页岩科技有限公司 Pyrimidine compound, its preparation method and medical application
RU2606949C9 (en) * 2015-11-19 2018-03-14 ЗАО "Р-Фарм" Substituted n-{3-[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-amides as modulators of egfr, applicable for treating cancer
RU2603960C1 (en) * 2015-11-19 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Dichloroacetate of n1,n2-disubstituted n4-[4-(1-methyl-1h-indole-3-yl)-pyrimidine-2-yl]-5-methoxybenzene-1,2,4-triamine as egfr modulator for treating cancer
TW201718583A (en) * 2015-11-23 2017-06-01 Nanjing Sanhome Pharmaceutical Co Ltd New epidermal growth factor receptor inhibitor and application thereof
CN106810553B (en) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3- (4, 5-substituted aminopyrimidine) phenyl derivative and application thereof
JP6978003B2 (en) * 2015-12-03 2021-12-08 チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド Heterocyclic compounds and their use
EP3383401B1 (en) * 2015-12-03 2020-05-20 Zheijiang Jianfreng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
CN105601620A (en) * 2015-12-25 2016-05-25 北京康立生医药技术开发有限公司 Method for preparing mereletinib mesylate
CN106928150B (en) 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 Acrylamide aniline derivative and pharmaceutical application thereof
KR20180105161A (en) 2016-01-07 2018-09-27 씨에스 파마테크 리미티드 Selective inhibitors of clinically important mutants of EGFR tyrosine kinase
CN105646454B (en) * 2016-01-19 2018-05-08 浙江大学 The 2- aryl amine pyridine derivatives of the fragment containing hydroxamic acid and preparation and application
CN106995437A (en) * 2016-01-22 2017-08-01 齐鲁制药有限公司 Substituted indole or indazole pyrimidine derivatives and its production and use
CN108530429B (en) * 2016-01-22 2021-04-27 焦玉奇 2- (2,4, 5-substituted aniline) pyrimidine derivatives
TWI745345B (en) * 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and “azd9291 aniline” or a salt thereof
CN107043368B (en) * 2016-02-05 2020-07-31 齐鲁制药有限公司 Crystals of arylamine pyrimidine compounds and salts thereof
CN107043369A (en) * 2016-02-06 2017-08-15 焦玉奇 2 (2,4,5 substituted aniline) pyrimidine derivatives
CN107098887B (en) * 2016-02-22 2019-08-09 复旦大学 Pyrimidines
CN105777716B (en) * 2016-02-25 2018-04-10 清华大学 A kind of EGFR inhibitor for targeted therapy of cancer and preparation method and application
CN105646467B (en) * 2016-02-25 2018-07-20 黄燕鸽 A kind of anticancer compound Aomei replaces Buddhist nun and its synthetic method
CN105585557B (en) * 2016-02-25 2018-06-22 清华大学 EGFR inhibitor for targeted therapy of cancer and preparation method and application
CN107163027B (en) * 2016-03-07 2019-11-05 上海艾力斯医药科技有限公司 Crystalline form of pyridylaminopyrimidine derivative mesylate and its preparation and application
CN107163026B (en) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 The salt and its preparation method and application of pyridine amine pyrimidine derivates
CN107188888A (en) * 2016-03-15 2017-09-22 罗欣生物科技（上海）有限公司 A kind of methanesulfonic acid for preparing steps the auspicious method for Buddhist nun
CN112645933B (en) * 2016-03-22 2022-02-11 江苏豪森药业集团有限公司 Polymorphic forms of an EGFR inhibitor free base or an acid salt thereof, methods of making and uses thereof
MX2018013602A (en) * 2016-05-11 2019-08-22 Beta Pharma Inc 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers.
AU2017267708B2 (en) 2016-05-19 2020-02-20 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
TW201800404A (en) * 2016-06-17 2018-01-01 貝達醫藥公司 Pharmaceutical salts of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
CN107522690B (en) * 2016-06-20 2022-08-05 海南先声药业有限公司 Preparation method of Osimetinib
CN107540661A (en) 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 Crystallization as the Aniline pyrimidine compound of EGFR inhibitor
CN107663208B (en) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 Medicinal salt of novel EGFR kinase inhibitor and preparation method and application thereof
CN107663207B (en) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 Mesylate crystal of EGFR kinase inhibitor and preparation method thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
ES2973283T3 (en) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam NMDA receptor modulators and uses thereof
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
ES2972533T3 (en) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam-based NMDA receptor modulators and their uses
EA201990424A1 (en) 2016-08-01 2019-08-30 Аптиникс Инк. SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
CN106366022B (en) * 2016-08-19 2018-03-13 上海工程技术大学 It is a kind of to be used to prepare AZD9291 intermediate and its preparation method and application
CN106366072B (en) * 2016-08-19 2018-12-07 上海工程技术大学 A kind of preparation method of AZD9291
CN106397407B (en) * 2016-08-31 2018-09-04 浙江科聚化工有限公司 The preparation method of antitumor drug AZD9291 derivatives
CN106432231B (en) * 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 The pharmaceutical salts and its crystal form and preparation method of AZD9291
ES2863925T3 (en) * 2016-09-19 2021-10-13 Nanjing Chuangte Pharmaceutical Tech Co Ltd Deuterated 3- (4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof
CN107955019B (en) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 Salt form and crystal form of EGFR inhibitor and preparation method thereof
WO2018073839A1 (en) 2016-10-18 2018-04-26 Mylan Laboratories Limited Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof
EP3528798A4 (en) * 2016-10-19 2020-10-21 United States Government as Represented by The Department of Veterans Affairs COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
CN106496196B (en) * 2016-10-20 2019-07-02 南京雷科星生物技术有限公司 A kind of quinazoline, Pyridopyrimidine or double and pyrimidine derivatives egf inhibitor and preparation method thereof and purposes
CN106543060B (en) * 2016-10-31 2018-11-06 湖南欧亚药业有限公司 A kind of difficult to understand this replaces the preparation method of Buddhist nun's mesylate
CN108299419B (en) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 Novel crystal forms of novel EGFR kinase inhibitor and preparation method thereof
PT3514153T (en) 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Pyrimidine compound and pharmaceutical use thereof
WO2018156812A1 (en) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
TWI796326B (en) 2017-03-24 2023-03-21 日商第一三共股份有限公司 Medicines containing axl inhibitor and egfr tyrosine kinase inhibitor and uses thereof
CN106883216B (en) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 Preparation method of oxitinib
CN108503627A (en) * 2017-04-19 2018-09-07 郑州泰基鸿诺医药股份有限公司 2,4- disubstituted benzenes -1,5- diamine derivatives as EGFR inhibitor and its application
AR111469A1 (en) * 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME
CN106967050A (en) * 2017-05-11 2017-07-21 北京工业大学 A kind of AZD9291 preparation method
CN108929311B (en) * 2017-05-22 2020-07-28 焦玉奇 2- (2,4, 5-substituted aniline) pyrimidine derivatives
WO2018214886A1 (en) 2017-05-24 2018-11-29 浙江同源康医药股份有限公司 Crystal form of deuterated azd9291, preparation method therefor, and use thereof
CN107176954B (en) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 A kind of pharmaceutical salts and its crystal form, preparation method and application of EGFR inhibitor
KR102388312B1 (en) * 2017-06-13 2022-04-19 베이징 아다메이들 바이오테크놀로지 리미티드 라이어빌리티 컴퍼니 Aminopyrimidine compound, preparation method and use thereof
TW201904577A (en) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-Dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl Pharmaceutical formulation of amino)phenyl) acrylamide and its salts
WO2019001425A1 (en) * 2017-06-27 2019-01-03 浙江同源康医药股份有限公司 Deuterated osimertinib derivative and application thereof
CN107095873A (en) * 2017-06-28 2017-08-29 卢凯华 Anti-lung cancer targeted medicament composition with low drug resistance
CN107216313B (en) * 2017-06-29 2019-11-19 山东四环药业股份有限公司 A preparation method of antitumor drug AZD9291
WO2019010619A1 (en) * 2017-07-10 2019-01-17 焦玉奇 2-(2,4,5-substituted aniline) pyrimidine derivative
JP7189932B2 (en) * 2017-07-28 2022-12-14 ユハン コーポレーション Intermediates useful for the synthesis of selective inhibitors of protein kinases and processes for their preparation
MY198379A (en) * 2017-07-28 2023-08-28 Yuhan Corp Improved Process for Preparing Aminopyrimidine Derivatives
CN107266426A (en) * 2017-08-15 2017-10-20 南通因诺威医药科技有限公司 2-Aminoalkylpyrimidines and their preparation and use
US11471457B2 (en) 2017-08-21 2022-10-18 Eli Lilly And Company Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
CN109485638B (en) * 2017-09-12 2020-07-17 新发药业有限公司 Preparation method of oxitinib intermediate
CN107915725B (en) * 2017-10-20 2023-06-27 复旦大学 Medicinal salt of AZD9291 and preparation method thereof
CA3082575A1 (en) * 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102761196B1 (en) 2018-01-31 2025-02-03 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 Spiro-lactam NMDA receptor modulators and uses thereof
US11465975B2 (en) 2018-02-08 2022-10-11 Neupharma, Inc Certain chemical entities, compositions, and methods
TW201941773A (en) 2018-02-12 2019-11-01 瑞典商阿斯特捷利康公司 Osimertinib for use in the treatment of non-small cell lung cancer
JP2021514011A (en) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Combination pharmaceutical preparation of EGFR inhibitor and its usage
CA3088972A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of egfr inhibitors and methods of use thereof
CN108250187B (en) * 2018-03-01 2021-01-05 中国科学院上海药物研究所 Indole-1-carbonate compound, its preparation method and application
CN108191861B (en) * 2018-03-01 2020-10-02 天津大学 N-[5-(Pyrimidine-2-amino)-2,4-disubstituted phenyl]-trans-2,4-pentadienamide
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
CN109666024A (en) * 2018-03-20 2019-04-23 兰州大学 2- oxygen pyrimidines and its preparation method and application
CN108218839A (en) * 2018-03-20 2018-06-29 上药康丽（常州）药业有限公司 A kind of preparation method of antitumor drug AZD9291
CN108484579A (en) * 2018-03-28 2018-09-04 黑龙江鑫创生物科技开发有限公司 A kind of micro passage reaction synthesis uncommon method for Buddhist nun's intermediate difficult to understand
CN108530450B (en) * 2018-05-03 2021-03-30 赖建智 Compound with EGFR (epidermal growth factor receptor) inhibitory activity, preparation method and application of compound in disease treatment
BR112020023107A2 (en) 2018-05-14 2021-02-02 Ariad Pharmaceuticals, Inc. pharmaceutical salts of pyrimidine derivatives and method of treating disorders
CN112119074A (en) 2018-05-15 2020-12-22 益方生物科技（上海）有限公司 EGFR inhibitors
CN110606842B (en) * 2018-06-15 2021-06-01 上海艾力斯医药科技股份有限公司 Process for producing pyridylamino pyrimidine derivative and intermediate thereof
CN110698461B (en) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 Preparation method of third-generation EGFR inhibitor
KR101954370B1 (en) 2018-07-25 2019-03-05 한미약품 주식회사 Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN109134435B (en) * 2018-10-29 2023-01-03 湖南大学 Synthesis method of AZD9291
CN111233774B (en) * 2018-11-28 2023-04-14 鲁南制药集团股份有限公司 Amino pyrimidine compound
BR112021011894A2 (en) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited PHARMACEUTICAL COMPOSITION
CN111410651B (en) * 2019-01-05 2021-06-04 山东轩竹医药科技有限公司 Salts of tyrosine kinase inhibitors and crystalline forms thereof
WO2020140934A1 (en) * 2019-01-05 2020-07-09 山东轩竹医药科技有限公司 Salt of selective inhibitor of egfr tyrosine kinase and crystal form thereof
PE20212153A1 (en) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING AN FLT3 INHIBITOR AND A HYPOMETHYLATING AGENT TO TREAT ACUTE MYELOID LEUKEMIA
CN109761960B (en) * 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 Preparation method of anti-drug and anti-tumor EGFR inhibitor
CN111606889B (en) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 Preparation method of 4-(1-cyclopropyl-1H-indol-3-yl)-N-phenylpyrimidin-2-amine derivative
CN109928956B (en) * 2019-02-27 2020-10-13 杭州偶联医药科技有限公司 Compound for targeted ubiquitination degradation of EGFR protein, and pharmaceutical composition and application thereof
WO2020192302A1 (en) * 2019-03-27 2020-10-01 广州必贝特医药技术有限公司 Pyrimidine-containing tri-substituted imidazole compound and application thereof
MX2021011810A (en) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer.
CN111747931A (en) 2019-03-29 2020-10-09 深圳福沃药业有限公司 Azaaromatic cyclic amide derivatives for the treatment of cancer
EA202100252A1 (en) * 2019-04-09 2022-03-10 Хэнань Дженьюин Биотек Ко., Лтд. DERIVATIVE OF 2-(2,4,5-SUBSTITUTED PHENYLAMINO)PYRIMIDINE AND ITS CRYSTAL FORM "B"
CN109942550A (en) * 2019-04-15 2019-06-28 广州医科大学附属第一医院（广州呼吸中心） 11EGFR positive electron tracer of C flag and its preparation method and application
BR112021020962A2 (en) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Pruritus treatment methods
TW202521536A (en) 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk inhibitors
KR20220011663A (en) * 2019-05-22 2022-01-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 Indole derivative-containing inhibitor, method for preparing the same, or application thereof
KR20210002015A (en) 2019-06-27 2021-01-06 한미약품 주식회사 A pharmaceutical composition comprising FLT3 inhibitor and chemotherapeutic agents for the treatment of the acute myeloid leukemia
CN110283162B (en) * 2019-07-09 2022-04-05 辽宁大学 A kind of epidermal growth factor receptor inhibitor and its application
CN110483486B (en) * 2019-09-17 2024-01-26 鲁南制药集团股份有限公司 Crystal form of oxtinib ketorolac and preparation method thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
IL272441B (en) * 2020-02-03 2021-08-31 Ottek Ltd System and method for endoscope propulsion
CN113372332B (en) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 Novel crystal form of octreotide
CN113372331B (en) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 Novel crystal form of Orientinib monohydrate
CN111303123B (en) * 2020-03-31 2021-08-31 南京雷正医药科技有限公司 2-(2,4,5-Substituted anilino)pyrimidine compound and its application
CN111285852A (en) * 2020-04-02 2020-06-16 广州博济医药生物技术股份有限公司 Crystal form of deuterated oxitinib medicinal salt and preparation method thereof
CN111303124A (en) * 2020-04-08 2020-06-19 北京赛思源生物医药技术有限公司 Novel crystal of oxitinib mesylate
US20210369709A1 (en) * 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN113801101A (en) * 2020-06-15 2021-12-17 鲁南制药集团股份有限公司 AZD 9291-2-ketoglutarate and preparation method thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113929663B (en) * 2020-06-29 2025-06-17 鲁南制药集团股份有限公司 AZD9291-2-indolecarboxylate and its preparation method
CN113929664A (en) * 2020-07-13 2022-01-14 鲁南制药集团股份有限公司 AZD9291-3, 5-pyridine dicarboxylic acid salt and preparation method thereof
CN113968845A (en) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 AZD 9291-gallate and preparation method thereof
US20230321098A1 (en) 2020-08-25 2023-10-12 Loxo Oncology, Inc. Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
KR20230094198A (en) 2020-09-23 2023-06-27 에라스카, 아이엔씨. Tricyclic pyridones and pyrimidones
CN112430231B (en) * 2020-11-06 2022-09-30 德州德药制药有限公司 Industrial preparation method of AZD9291
CN112358468B (en) * 2020-11-10 2022-03-22 德州德药制药有限公司 Industrial synthesis method of AZD9291
TW202222795A (en) * 2020-11-19 2022-06-16 大陸商上海翰森生物醫藥科技有限公司 The salt, crystal form and preparation method of an indole-containing derivative
US11780824B2 (en) 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP4355330A1 (en) 2021-06-15 2024-04-24 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
CN113387935B (en) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 Compound for inhibiting triple-mutation epidermal growth factor receptor tyrosine kinase and application thereof
CA3224289A1 (en) * 2021-08-06 2023-02-09 Tao Feng Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy
AU2022340897A1 (en) 2021-09-02 2024-03-14 Synthon B.V. A process for making osimertinib
CN113683612B (en) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 Preparation method of palbociclib
JP7702205B2 (en) * 2021-09-15 2025-07-03 株式会社東芝 Novel amine compound, acidic gas absorbent, method for removing acidic gas, and method for removing acidic gas
CN116099006A (en) * 2021-11-10 2023-05-12 上海交通大学医学院附属新华医院 Application of osimertinib and pharmaceutically acceptable salts thereof in the preparation of medicines for acute myeloid leukemia
CN114014847B (en) * 2021-12-08 2023-11-03 滨州医学院 A kind of benzothiophene-containing pyrimidine derivative, its preparation method and its application in preparing anti-tumor drugs
CN114380806B (en) * 2022-03-24 2022-06-10 中国药科大学 2-Amino-4-indolylpyrimidine compounds and preparation method and application thereof
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
AR128999A1 (en) 2022-04-07 2024-07-03 Astrazeneca Ab IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB
CA3249080A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
EP4518858A1 (en) * 2022-05-03 2025-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Inhibitors of tau proteins
KR20250029133A (en) 2022-06-27 2025-03-04 아스트라제네카 아베 Combinations comprising epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
CN119654152A (en) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 Epidermal growth factor receptor tyrosine kinase inhibitors for use in combination with HGF-receptor inhibitors in the treatment of cancer
CN115650974B (en) * 2022-08-04 2024-06-18 天津大学 N-[5-(pyrimidine-2-amino)-2,4-disubstituted phenyl]-cis-pentadienamide derivatives and applications
CN119894871A (en) * 2022-09-19 2025-04-25 南京爱德程医药科技有限公司 Pyrimidine compounds as kinase inhibitors having biological activity against EGFR mutants
CN116655601B (en) * 2023-06-05 2025-08-29 河南应用技术职业学院 A synthetic method of osimertinib
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (en) 1996-03-05 2002-06-28 Astrazeneca Ab 4-ANYLINOQUINAZOLINE DERIVATIVES
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (en) 1999-02-10 2023-05-02 Astrazeneca Ab COMPOUND
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
MXPA02012905A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents.
BR0112225A (en) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Compound, pharmaceutical composition, use of a compound, and process for preparing a compound
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (en) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
DE602005014382D1 (en) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl pyrazolopyridine ERBB Kinase Inhibitors
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
RU2405566C9 (en) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Method of treating gefitinib-resistant cancer
CN101316597B (en) 2005-11-03 2013-04-17 顶点医药品公司 Aminopyrimidines useful as kinase inhibitors
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
JP5103403B2 (en) * 2005-12-05 2012-12-19 スミスクライン ビーチャム コーポレーション 2-pyrimidinylpyrazolopyridine ErbB kinase inhibitor
CA2659582A1 (en) 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
EP2046759A1 (en) * 2006-07-21 2009-04-15 Novartis AG 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
JP5600063B2 (en) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2361248B1 (en) * 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
CN105574346A (en) 2008-09-05 2016-05-11 新基阿维罗米克斯研究公司 Design method and detection method for polypeptide conjugate and irreversible inhibitor
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (en) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 Kinase suppressor and pharmaceutical application thereof
JP5918693B2 (en) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド EGFR inhibitor and disease treatment method
KR101256018B1 (en) * 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
CN102725292A (en) * 2009-11-02 2012-10-10 雅培制药有限公司 Imidazolopyridine compounds as new constructs for multi-target kinase inhibition
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
CA2803056C (en) 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
EP2704572B1 (en) * 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
PT3009431T (en) 2011-07-27 2017-12-26 Astrazeneca Ab 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer

Also Published As

Publication number Publication date
LT3009431T (en) 2018-01-10
DK3686194T3 (en) 2021-11-22
BR122014026150B1 (en) 2020-10-13
KR101410902B1 (en) 2014-06-20
PL3333161T3 (en) 2020-08-24
US11524951B2 (en) 2022-12-13
HRP20171957T1 (en) 2018-02-09
EA029488B1 (en) 2018-04-30
DOP2013000263A (en) 2014-01-31
US20130053409A1 (en) 2013-02-28
SG10201910984XA (en) 2020-01-30
PT3009431T (en) 2017-12-26
IL229199A (en) 2015-11-30
RS54653B1 (en) 2016-08-31
CY1123210T1 (en) 2021-10-29
EP4119551A1 (en) 2023-01-18
AR087336A1 (en) 2014-03-19
US20210130318A1 (en) 2021-05-06
EA201792394A3 (en) 2018-07-31
CA2881991C (en) 2016-10-25
US20240182441A1 (en) 2024-06-06
CN103702990B (en) 2015-09-09
SG10201402857QA (en) 2014-08-28
RS56679B1 (en) 2018-03-30
LT3686194T (en) 2021-11-25
ME02887B (en) 2018-04-20
JP5537704B2 (en) 2014-07-02
TW201443040A (en) 2014-11-16
SI3009431T1 (en) 2018-01-31
CA2881993A1 (en) 2013-01-31
PT3686193T (en) 2022-05-20
CN104109151A (en) 2014-10-22
PE20141700A1 (en) 2014-11-20
BR122014026114B1 (en) 2021-01-12
TWI555743B (en) 2016-11-01
AU2012288626A1 (en) 2013-05-02
IL229199A0 (en) 2014-01-30
EP3333161B1 (en) 2020-02-19
PL2736895T3 (en) 2016-05-31
CN104109161B (en) 2016-08-17
CL2013003281A1 (en) 2014-07-25
CN104109151B (en) 2017-04-12
TWI583386B (en) 2017-05-21
PH12015501326B1 (en) 2015-09-14
CN105175396B (en) 2018-01-16
WO2013014448A1 (en) 2013-01-31
EP3009431B1 (en) 2017-10-25
CN104109161A (en) 2014-10-22
US20180162832A1 (en) 2018-06-14
JP5427321B2 (en) 2014-02-26
GT201300288A (en) 2017-10-09
SMT201600070B (en) 2016-04-29
IL242285A (en) 2016-07-31
IL242284A0 (en) 2015-11-30
BR122014026094B1 (en) 2020-10-13
BR112014001768A2 (en) 2017-02-14
HK1256370A1 (en) 2019-09-20
HK1192549A1 (en) 2014-08-22
DK3009431T3 (en) 2018-01-08
EA024421B1 (en) 2016-09-30
CO6811863A2 (en) 2013-12-16
CA2881987C (en) 2017-04-25
US10017493B2 (en) 2018-07-10
DK3333161T3 (en) 2020-05-18
US10858336B2 (en) 2020-12-08
RS62542B1 (en) 2021-12-31
HUE049060T2 (en) 2020-08-28
NZ617393A (en) 2014-11-28
EA033733B1 (en) 2019-11-20
PT3333161T (en) 2020-05-18
SMT202100652T1 (en) 2022-01-10
KR101422619B1 (en) 2014-07-24
SI3333161T1 (en) 2020-07-31
IL242285A0 (en) 2015-11-30
US20240425476A1 (en) 2024-12-26
BR122014026114A2 (en) 2019-08-20
CN105348266B (en) 2018-04-10
US20150119379A1 (en) 2015-04-30
PL3009431T3 (en) 2018-02-28
IL242286A (en) 2016-07-31
MY161925A (en) 2017-05-15
US8946235B2 (en) 2015-02-03
MX2020013020A (en) 2022-06-14
CA2843109C (en) 2015-06-16
JP2014139226A (en) 2014-07-31
ES2654177T3 (en) 2018-02-12
CY1120072T1 (en) 2018-12-12
BR122014026094A2 (en) 2019-08-20
CA2881987A1 (en) 2013-01-31
DK2736895T3 (en) 2016-02-29
SG10201910986QA (en) 2020-01-30
EP4086246A1 (en) 2022-11-09
EP3686194B1 (en) 2021-09-15
PT3686194T (en) 2021-11-11
EP2736895B1 (en) 2016-01-06
TW201319057A (en) 2013-05-16
EP3686194A1 (en) 2020-07-29
ME03785B (en) 2021-04-20
ES2914854T3 (en) 2022-06-17
HK1192554A1 (en) 2014-08-22
JP2013544273A (en) 2013-12-12
HRP20160135T1 (en) 2016-03-11
KR20140047741A (en) 2014-04-22
CA2881991A1 (en) 2013-01-31
SG10201402860QA (en) 2014-08-28
IL242278A0 (en) 2015-11-30
TWI465445B (en) 2014-12-21
IL242279A (en) 2016-07-31
ES2791308T3 (en) 2020-11-03
EA201792394A2 (en) 2018-03-30
US20190389834A1 (en) 2019-12-26
US20190092746A1 (en) 2019-03-28
LT3333161T (en) 2020-05-11
EA201690328A1 (en) 2016-11-30
KR20140030089A (en) 2014-03-11
HRP20211682T1 (en) 2022-03-04
IL242278A (en) 2016-12-29
CA2882018C (en) 2017-04-25
UY34219A (en) 2013-02-28
CN105198862A (en) 2015-12-30
HUE026429T2 (en) 2016-05-30
HUE037645T2 (en) 2018-09-28
MX2014000528A (en) 2014-05-01
AU2012288626C1 (en) 2015-09-17
CA2843109A1 (en) 2013-01-31
IL242279A0 (en) 2015-11-30
JP2014094930A (en) 2014-05-22
PL3686193T3 (en) 2022-06-13
EP2736895A1 (en) 2014-06-04
HUE056365T2 (en) 2022-02-28
MY194532A (en) 2022-11-30
NI201300134A (en) 2014-02-12
SG194783A1 (en) 2013-12-30
ME02382B (en) 2016-06-20
EP3686193A1 (en) 2020-07-29
HRP20200624T1 (en) 2020-07-10
EP3009431A1 (en) 2016-04-20
EP3333161A1 (en) 2018-06-13
PH12015501326A1 (en) 2015-09-14
RS60190B1 (en) 2020-06-30
AU2012288626A8 (en) 2013-09-26
DK3686193T3 (en) 2022-05-30
IL242284A (en) 2016-07-31
HK1221216A1 (en) 2017-05-26
ES2564671T3 (en) 2016-03-28
IL242286A0 (en) 2015-11-30
PL3686194T3 (en) 2022-01-17
JP5977779B2 (en) 2016-08-24
EA201391491A1 (en) 2014-08-29
CN105175396A (en) 2015-12-23
EP3686193B1 (en) 2022-03-02
CN105348266A (en) 2016-02-24
BR112014001768B1 (en) 2019-02-05
CN105254616A (en) 2016-01-20
CA2882018A1 (en) 2013-01-31
MX377900B (en) 2025-03-10
KR101691268B1 (en) 2016-12-29
CA2881993C (en) 2017-05-09
ECSP13013033A (en) 2014-01-31
US9732058B2 (en) 2017-08-15
SMT202000208T1 (en) 2020-05-08
SI2736895T1 (en) 2016-03-31
CR20130629A (en) 2014-03-12
AU2012288626B2 (en) 2015-05-07
CY1125405T1 (en) 2023-03-24
CN105198862B (en) 2018-01-23
BR122014026150A2 (en) 2019-05-28
CY1117431T1 (en) 2017-04-26
CN105254616B (en) 2017-10-17
KR20140062181A (en) 2014-05-22
TW201700099A (en) 2017-01-01
PH12013502312A1 (en) 2016-07-13
ES2900230T3 (en) 2022-03-16
CN103702990A (en) 2014-04-02

Similar Documents

Publication Publication Date Title
PL3686193T3 (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
IL286152A (en) Substituted imidazopyridinyl-aminopyridine compounds
SI2694508T1 (en) Substituted 2,3-dihydroimidazoš1,2-cćquinazoline salts
IL229007A0 (en) Parasiticidal dihydrosioxazole compounds
EP2699091A4 (en) 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
GB201117019D0 (en) Herbicidal compounds
GB201012105D0 (en) Novel pyrimidine compounds
EP2709609A4 (en) Heterocyclic compounds
PL2793589T3 (en) Herbicidal compounds
ZA201306229B (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines
IL233800A0 (en) Fungicidal pyrimidine compounds
IL228651A0 (en) Herbicidal compounds
IL231468A0 (en) 1,3-diaryl-substituted heterocyclic pesticides
IL233799A0 (en) Fungicidal pyrimidine compounds
GB2501403B (en) 3-arylethynyl substituted quinazolinone compounds
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101821D0 (en) Novel heterocyclic compounds 1
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201113448D0 (en) Novel compounds 61
GB201103074D0 (en) Novel compounds 1
GB201113450D0 (en) Novel compounds 60
GB201101824D0 (en) Novel heteroclyclic compounds 5
GB201113443D0 (en) Novel compounds 62
GB201113441D0 (en) Novel compounds 64